Why Cadre Holdings (CDRE) Is Getting Attention Now
Cadre Holdings, Inc. CDRE | 0.00 |
Why Cadre Holdings Stock Is Back On Investors’ Radar
Cadre Holdings (CDRE) is in focus after reporting second quarter 2026 results that showed higher year over year sales, raised full year net sales guidance, and a small non cash impairment charge.
Cadre Holdings shares trade at US$32.76. The stock has seen a 13.16% 1 month share price return and a 15.43% 3 month share price return. The 1 year total shareholder return of 16.51% and 3 year total shareholder return of 34.39% point to momentum that has built despite a year to date share price decline of 20.33%.
If you are looking beyond Cadre Holdings after this earnings update, it can be worth scanning other opportunities that fit a strong business story. One way to do that is by checking the 19 top founder-led companies
After a sharp rebound from the recent pullback and fresh guidance for higher 2026 net sales, the key issue is simple. At around US$32.76, does Cadre Holdings still offer an attractive risk reward, or has most of the upside already been priced in?
Most Popular Narrative: 30% Undervalued
The most followed narrative values Cadre Holdings at $46.80 per share, which sits well above the last close of $32.76 and frames the current debate about upside.
Ongoing global instability and public safety concerns are driving higher and recurring demand for Cadre's protective equipment and nuclear safety products, supporting consistent long-term revenue growth across core markets, with additional benefit expected as delayed government contracts are fulfilled. Continued increases in government investment, especially in law enforcement, military, border security, and nuclear sectors, are expected to drive steady procurement cycles and fund expansion of Cadre's customer base, providing visibility and resiliency for revenues.
Want to see what is baked into that $46.80 fair value for Cadre Holdings? The narrative leans heavily on future earnings power, richer margins and a premium profit multiple that many investors reserve for faster growing sectors.
Result: Fair Value of $46.80 (UNDERVALUED)
However, the Cadre Holdings story can shift quickly if large government contracts are delayed again or if M&A integration costs continue to pressure near term profitability.
Another View On Cadre Holdings Valuation
The SWS DCF model values Cadre Holdings at $51.18 per share, compared with the current price of $32.76. That implies the stock is trading at a discount using future cash flow assumptions, while the current P/E of 38.9x sits above a fair ratio of 32.9x. Which signal do you place more weight on?
Next Steps
The mixed sentiment around Cadre Holdings, with both clear risks and appealing rewards, makes this a moment to look closely at the details yourself. If you want a concise summary of what stands out on both sides of the story, take a look at the 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Cadre Holdings?
If Cadre Holdings has your attention, do not stop here. Broaden your watchlist with fresh stock ideas that match the kind of quality and risk profile you care about.
- Target dependable income by checking out 9 dividend fortresses that focus on higher yielding companies with the potential to support regular payouts.
- Hunt for potential bargains using the screener containing 21 high quality undiscovered gems to surface under the radar stocks with strong underlying fundamentals.
- Prioritise resilience with the 83 resilient stocks with low risk scores that highlight companies screened for more stable risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
